{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T04:08:59Z","timestamp":1773374939013,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,12]]},"DOI":"10.7759\/cureus.105120","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:49:26Z","timestamp":1773341366000},"source":"Crossref","is-referenced-by-count":0,"title":["Association Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Antivascular Endothelial Growth Factor-Related Proteinuria in Solid Tumors: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Ryuichi","family":"Ohta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100620","article-title":"Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy","volume":"32","author":"Elebiyo TC","year":"2022","unstructured":"Elebiyo TC, Rotimi D, Evbuomwan IO, et al.. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. Cancer Treat Res Commun. 2022, 32:100620. 10.1016\/j.ctarc.2022.100620","journal-title":"Cancer Treat Res Commun"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16626","article-title":"Vascular endothelial growth factor family and head and neck squamous cell carcinoma","volume":"43","author":"Dumitru CS","year":"2023","unstructured":"Dumitru CS, Raica M. Vascular endothelial growth factor family and head and neck squamous cell carcinoma. Anticancer Res. 2023, 43:4315-26. 10.21873\/anticanres.16626","journal-title":"Anticancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(01)00556-3","article-title":"Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications","volume":"2","author":"Toi M","year":"2001","unstructured":"Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2001, 2:667-73. 10.1016\/S1470-2045(01)00556-3","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00081.2025","article-title":"Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors","volume":"329","author":"Uyl TJ","year":"2025","unstructured":"Uyl TJ, Ngo A, Pratt D, et al.. Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors. Am J Physiol Renal Physiol. 2025, 329:F284-99. 10.1152\/ajprenal.00081.2025","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.02.003","article-title":"Effect of intravitreal anti-endothelial growth factor agents on renal function in patients with diabetes mellitus","volume":"9","author":"Rivero M","year":"2024","unstructured":"Rivero M, Fern\u00e1ndez-Vidal M, Sandino J, et al.. Effect of intravitreal anti-endothelial growth factor agents on renal function in patients with diabetes mellitus. Kidney Int Rep. 2024, 9:1397-405. 10.1016\/j.ekir.2024.02.003","journal-title":"Kidney Int Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-024-03990-1","article-title":"Ocular and systemic vascular endothelial growth factor ligand inhibitor use and nephrotoxicity: an update","volume":"56","author":"Rangaswamy D","year":"2024","unstructured":"Rangaswamy D, Nagaraju SP, Bhojaraja MV, Swaminathan SM, Prabhu RA, Rao IR, Shenoy SV. Ocular and systemic vascular endothelial growth factor ligand inhibitor use and nephrotoxicity: an update. Int Urol Nephrol. 2024, 56:2635-44. 10.1007\/s11255-024-03990-1","journal-title":"Int Urol Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.75","article-title":"Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis","volume":"75","author":"Avihingsanon Y","year":"2009","unstructured":"Avihingsanon Y, Benjachat T, Tassanarong A, Sodsai P, Kittikovit V, Hirankarn N. Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis. Kidney Int. 2009, 75:1340-8. 10.1038\/ki.2009.75","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman SR","year":"2012","unstructured":"Hayman SR, Leung N, Grande JP, Garovic VD. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012, 14:285-94. 10.1007\/s11912-012-0242-z","journal-title":"Curr Oncol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.07.002","article-title":"Renin-angiotensin-aldosterone system modulates blood pressure response during vascular endothelial growth factor receptor inhibition","volume":"1","author":"Bottinor WJ","year":"2019","unstructured":"Bottinor WJ, Shuey MM, Manouchehri A, et al.. Renin-angiotensin-aldosterone system modulates blood pressure response during vascular endothelial growth factor receptor inhibition. JACC CardioOncol. 2019, 1:14-23. 10.1016\/j.jaccao.2019.07.002","journal-title":"JACC CardioOncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028050","article-title":"Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise: a clinical cohort study","volume":"12","author":"van Dorst DC","year":"2023","unstructured":"van Dorst DC, Kabadayi S, Oomen-de Hoop E, Danser AH, Mathijssen RH, Versmissen J. Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise: a clinical cohort study. J Am Heart Assoc. 2023, 12:e028050. 10.1161\/JAHA.122.028050","journal-title":"J Am Heart Assoc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13639","article-title":"Renin-angiotensin inhibition in combating malignancy: a review","volume":"39","author":"Rosenthal T","year":"2019","unstructured":"Rosenthal T, Gavras I. Renin-angiotensin inhibition in combating malignancy: a review. Anticancer Res. 2019, 39:4597-602. 10.21873\/anticanres.13639","journal-title":"Anticancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda Y","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013, 48:452-8. 10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3580-1","article-title":"Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab","volume":"81","author":"Nihei S","year":"2018","unstructured":"Nihei S, Sato J, Harada T, et al.. Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab. Cancer Chemother Pharmacol. 2018, 81:1051-9. 10.1007\/s00280-018-3580-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03876-5","article-title":"Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis","volume":"84","author":"Hirai T","year":"2019","unstructured":"Hirai T, Shuji Y, Takiyama M, Hanada K, Itoh T. Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis. Cancer Chemother Pharmacol. 2019, 84:195-202. 10.1007\/s00280-019-03876-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3892\/br.2022.1559","article-title":"Renin-angiotensin system inhibitors may have an advantage over calcium channel blockers in reducing proteinuria in gastric cancer patients receiving ramucirumab","volume":"17","author":"Chiba T","year":"2022","unstructured":"Chiba T, Ujiie H, Yaegashi Y, et al.. Renin-angiotensin system inhibitors may have an advantage over calcium channel blockers in reducing proteinuria in gastric cancer patients receiving ramucirumab. Biomed Rep. 2022, 17:76. 10.3892\/br.2022.1559","journal-title":"Biomed Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04408-4","article-title":"Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib","volume":"89","author":"Ikesue H","year":"2022","unstructured":"Ikesue H, Yamaoka K, Matsumoto A, et al.. Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. Cancer Chemother Pharmacol. 2022, 89:833-8. 10.1007\/s00280-022-04408-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0289950","article-title":"Bevacizumab-induced proteinuria and its association with antihypertensive drugs: a retrospective cohort study using a Japanese administrative database","volume":"18","author":"Kiyomi A","year":"2023","unstructured":"Kiyomi A, Koizumi F, Imai S, Yamana H, Horiguchi H, Fushimi K, Sugiura M. Bevacizumab-induced proteinuria and its association with antihypertensive drugs: a retrospective cohort study using a Japanese administrative database. PLoS One. 2023, 18:e0289950. 10.1371\/journal.pone.0289950","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.02.042","article-title":"Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging\u00a0evidence","volume":"96","author":"Hanna RM","year":"2019","unstructured":"Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging\u00a0evidence. Kidney Int. 2019, 96:572-80. 10.1016\/j.kint.2019.02.042","journal-title":"Kidney Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02249-0","article-title":"Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives","volume":"10","author":"Lee C","year":"2025","unstructured":"Lee C, Kim MJ, Kumar A, Lee HW, Yang Y, Kim Y. Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives. Signal Transduct Target Ther. 2025, 10:170. 10.1038\/s41392-025-02249-0","journal-title":"Signal Transduct Target Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.14210","article-title":"A prospective comparison of azilsartan and amlodipine for bevacizumab-induced hypertension and proteinuria in colorectal cancer","volume":"40","author":"Nihei S","year":"2026","unstructured":"Nihei S, Ujiie H, Saito K, et al.. A prospective comparison of azilsartan and amlodipine for bevacizumab-induced hypertension and proteinuria in colorectal cancer. In Vivo. 2026, 40:465-73. 10.21873\/invivo.14210","journal-title":"In Vivo"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2018.1544639","article-title":"Outcome of bevacizumab therapy in patients with recurrent glioblastoma treated with angiotensin system inhibitors","volume":"36","author":"Johansen MD","year":"2018","unstructured":"Johansen MD, Urup T, Holst CB, et al.. Outcome of bevacizumab therapy in patients with recurrent glioblastoma treated with angiotensin system inhibitors. Cancer Invest. 2018, 36:512-9. 10.1080\/07357907.2018.1544639","journal-title":"Cancer Invest"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312941","article-title":"Pharmacological nephroprotection in chronic kidney disease patients with type 2 diabetes mellitus-clinical practice position statement of the Polish Society of Nephrology","volume":"25","author":"Adamczak M","year":"2024","unstructured":"Adamczak M, Kurnatowska I, Naumnik B, Stomp\u00f3r T, Tylicki L, Krajewska M. Pharmacological nephroprotection in chronic kidney disease patients with type 2 diabetes mellitus-clinical practice position statement of the Polish Society of Nephrology. Int J Mol Sci. 2024, 25:12941. 10.3390\/ijms252312941","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60111821","article-title":"Proteinuria and progression of renal damage: the main pathogenetic mechanisms and pharmacological approach","volume":"60","author":"Longhitano E","year":"2024","unstructured":"Longhitano E, Calabrese V, Casuscelli C, et al.. Proteinuria and progression of renal damage: the main pathogenetic mechanisms and pharmacological approach. Medicina (Kaunas). 2024, 60:1821. 10.3390\/medicina60111821","journal-title":"Medicina (Kaunas)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.93707","article-title":"ACE inhibitors and ARBs in chronic kidney disease: a systematic review of randomized controlled trials on albuminuria reduction, eGFR decline, and safety","volume":"17","author":"Avula A","year":"2025","unstructured":"Avula A, Johal LK, Ali F, et al.. ACE inhibitors and ARBs in chronic kidney disease: a systematic review of randomized controlled trials on albuminuria reduction, eGFR decline, and safety. Cureus. 2025, 17:e93707. 10.7759\/cureus.93707","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/470382-association-between-angiotensin-converting-enzyme-inhibitors-and-angiotensin-ii-receptor-blockers-with-antivascular-endothelial-growth-factor-related-proteinuria-in-solid-tumors-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:49:27Z","timestamp":1773341367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/470382-association-between-angiotensin-converting-enzyme-inhibitors-and-angiotensin-ii-receptor-blockers-with-antivascular-endothelial-growth-factor-related-proteinuria-in-solid-tumors-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.105120","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}